welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
study id #: NCT03400852
condition: Muscular Dystrophy, Duchenne
status: terminated
purpose:This is a multicenter, double blind, placebo controlled, multiple dose study to examine the safety and efficacy of MNK-1411 in male subjects 4 to 8 years of age (inclusive) with Duchenne Muscular Dystrophy (DMD).
intervention: Cosyntropin, Placebo
mechanism of action: Melanocortin receptor agonist to reduce inflammation and muscle damage
results: https://clinicaltrials.gov/ct2/show/results/NCT03400852
last updated: August 26, 2020
rareRelated
-
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
-
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrop...To Assess the Activity and Safety of SMT...
-
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
-
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
-
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
-
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...
-
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyThe purpose of the study is to see wheth...
-
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
-
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
Mallinckrodt’s MNK-1411 gets orphan drug status for DMDMallinckrodt plc MNK announced that the ...
-
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...